Adverse Events Reported Following Live, Cold-Adapted, Intranasal Influenza Vaccine
Open Access
- 7 December 2005
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 294 (21), 2720-2725
- https://doi.org/10.1001/jama.294.21.2720
Abstract
Annual influenza vaccination is the primary method for protection against influenza illness.1 Until the 2002-2003 influenza season, the only licensed influenza vaccine in the United States was the inactivated, trivalent injectable vaccine, with recommendations emphasizing use among individuals for whom influenza is of particular concern.1,2 In June 2003, the US Food and Drug Administration (FDA) licensed a trivalent live, attenuated influenza vaccine (LAIV-T [FluMist, MedImmune Vaccines Inc, Gaithersburg, Md]) for intranasal use among healthy persons 5 to 49 years of age.3 Each dose contains live attenuated influenza virus reassortants of the 3 strains recommended by the US Public Health Service for the corresponding influenza season.2,3Keywords
This publication has 8 references indexed in Scilit:
- Live Attenuated Influenza Vaccine, Trivalent, Is Safe in Healthy Children 18 Months to 4 Years, 5 to 9 Years, and 10 to 18 Years of Age in a Community-Based, Nonrandomized, Open-Label TrialPediatrics, 2005
- Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescentsThe Pediatric Infectious Disease Journal, 2004
- Risk of Anaphylaxis After Vaccination of Children and AdolescentsPublished by American Academy of Pediatrics (AAP) ,2003
- Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthmaThe Pediatric Infectious Disease Journal, 2002
- The vaccine adverse event reporting system.Journal of Toxicology: Clinical Toxicology, 1998
- The reporting sensitivities of two passive surveillance systems for vaccine adverse events.American Journal of Public Health, 1995
- The vaccine adverse event reporting system (VAERS)Vaccine, 1994
- AN EPIDEMIOLOGIC AND CLINICAL EVALUATION OF GUILLAIN-BARRÉ SYNDROME REPORTED IN ASSOCIATION WITH THE ADMINISTRATION OF SWINE INFLUENZA VACCINESAmerican Journal of Epidemiology, 1984